Function
Locations
Pre-receptor amplification of glucocorticoid action in liver, adipose and brain; direction set by H6PD-supplied NADPH. Metabolic-syndrome drug target; cortisone reductase deficiency when impaired.
Tissue glucocorticoid action is set not only by circulating cortisol but by local, pre-receptor interconversion between active cortisol and inactive cortisone, catalysed by two endoplasmic-reticulum-membrane 11beta-hydroxysteroid dehydrogenases with opposite directionality. 11beta-HSD type 1 (HSD11B1) acts predominantly as an NADPH-dependent reductase — its direction fixed by NADPH generated in the ER lumen by hexose-6-phosphate dehydrogenase (H6PD) — regenerating active cortisol from cortisone and thereby amplifying glucocorticoid signalling in liver, adipose tissue and brain (a validated metabolic-syndrome drug target). 11beta-HSD type 2 (HSD11B2) is an NAD+-dependent, essentially unidirectional dehydrogenase that inactivates cortisol to cortisone; in aldosterone-target epithelia (distal nephron, colon, salivary gland) it destroys cortisol locally so that the non-selective mineralocorticoid receptor is protected from illicit activation by cortisol, conferring aldosterone specificity, and in the placenta it shields the fetus from maternal glucocorticoid. Loss of HSD11B2 causes apparent mineralocorticoid excess (AME), a severe juvenile hypertension with hypokalaemia; altered HSD11B1 activity underlies cortisone reductase deficiency and is implicated in the metabolic syndrome.
All recommended fields populated.
✗ none found
No MODULE:cortisol_cortisone_shuttle deep-research report alongside the module YAML.
✓ every leaf node grounds to a representative protein.
✓ every declared conforms_to bundle matches its template motif.
2 complete review(s) · 0 with deep research · 0 missing review · 2 reviewed but lacking deep research
| Gene | Review | Complete | Deep research |
|---|---|---|---|
| HSD11B1 P28845 | ✓ | ✓ | ✗ |
| HSD11B2 P80365 | ✓ | ✓ | ✗ |
Pre-receptor cortisol<->cortisone shuttle grounded to the human enzymes HSD11B1 (UniProtKB:P28845, GO:0070524, NADP+-dependent, EC 1.1.1.146) and HSD11B2 (P80365, GO:0070523, NAD+-dependent, EC 1.1.1.-). The two enzymes catalyse the same chemical interconversion in opposite directions, so the module is a cycle rather than a linear pathway: HSD11B1 predominantly reduces cortisone to active cortisol (its direction fixed by ER-lumenal H6PD NADPH), while HSD11B2 unidirectionally oxidises cortisol to inactive cortisone. GO molecular-function/location terms were taken from the completed human gene reviews and verified against the local go.db; the shared human Reactome reaction R-HSA-194023 (cortisol->cortisone) was verified against the local reactome cache. Each enzyme uses a PANTHER family selector with the human protein as representative so the module generalises across orthologs/paralogs. Physiologically this shuttle sets tissue glucocorticoid tone: HSD11B1 amplifies it (liver/adipose/brain; metabolic-syndrome target), HSD11B2 confers aldosterone specificity on the mineralocorticoid receptor (kidney/colon) and protects the fetus (placenta). Disorders: apparent mineralocorticoid excess (HSD11B2), cortisone reductase deficiency and metabolic-syndrome association (HSD11B1). Upstream cortisol is made by the adrenal steroidogenesis module (CYP11B1); the sex-steroid biosynthesis enzymes are a separate module.
Pre-receptor amplification of glucocorticoid action in liver, adipose and brain; direction set by H6PD-supplied NADPH. Metabolic-syndrome drug target; cortisone reductase deficiency when impaired.
Protects the non-selective mineralocorticoid receptor from cortisol in the distal nephron/colon and shields the fetus in placenta. Deficiency = apparent mineralocorticoid excess (AME), severe juvenile hypertension.